TB Research

Nosiheptide Harbors Potent <i>In Vitro</i> and Intracellular Inhbitory Activities against Mycobacterium tuberculosis

Xia Yu, Rui Zhu, Zhi Geng, Yaoyao Kong, Fen Wang, Lingling Dong, Liping Zhao, Yi Xue, et al. (10 authors)

Microbiology Spectrum · 2022-10

Abstract

This study is aimed at chemotherapy for MDR-TB, mainly to explore the anti-TB activity of the existing chemotherapeutic reagent. We found that NOS has potent inhibitory activities against M. tuberculosis in vitro regardless of the drug-resistant profile. Furthermore, NOS also showed the long PAE and partial synergistic effect with INH and is nontoxic, providing support for its promise as a drug candidate for drug-resistant tuberculosis treatment.

MeSH terms

  • Rifampicin
  • Tuberculosis
  • Mycobacterium tuberculosis
  • Isoniazid
  • Minimum inhibitory concentration
  • Microbiology
  • In vitro
  • Medicine
  • Antibiotics
  • Mycobacterium
  • Pharmacology
  • Biology